{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-164527","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2025-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.340728+00:00","generated_at":"2026-05-18T00:48:49.697548+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Edwards Lifesciences EVP Larry Wood to resign; Daniel Lippis to lead TAVR business","bullets":["Larry Wood, Corporate VP and Group President of TAVR and Surgical Structural Heart, resigns effective Sept 1, 2025.","Wood departs to accept a senior leadership role at another company outside cardiovascular.","Daniel J. Lippis, current Corporate VP for Japan, Greater China, and Asia Pacific, will succeed as Corporate VP for TAVR.","The transition is effective September 1, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-164527","json":"https://secwatch.observer/filing/0001193125-25-164527.json","markdown":"https://secwatch.observer/filing/0001193125-25-164527.md","text":"https://secwatch.observer/filing/0001193125-25-164527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000119312525164527/0001193125-25-164527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000119312525164527/d66195d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T00:48:49.697548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}